Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Series Vol. 6 , 03 August 2023
* Author to whom correspondence should be addressed.
Alzheimer’s disease (AD) is a kind of neurodegeneration disease and often happens in older people. Age is an influencing factor in the prevalence of AD. Up to now, AD is still difficult to cure and only limited medications can relieve some of the symptoms. Therefore, research on the pathology of neurodegenerative diseases has become more and more popular in recent years. Multiple studies offer some proof that the tau protein mutation and AD are related. This review described the structure and the purpose of the tau protein. The linkage between abnormal tau mutation and AD is further clarified, and a summary of two medications for AD is also included.
Alzheimer’s disease, AD, tau protein, abnormal amyloid beta, Acetylcholinesterase inhibitors
1. Alzheimer Disease—StatPearls—NCBI Bookshelf. (n.d.). Retrieved 8 January 2023, from https://www.ncbi.nlm.nih.gov/books/NBK499922/.
2. Čolović, M. B., Krstić, D. Z., Lazarević-Pašti, T. D., Bondžić, A. M. and Vasić, V. M. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Current Neuropharmacology 11(3), 315–335 (2013). https://doi.org/10.2174/1570159X11311030006.
3. Avila, J., Jiménez, J. S., Sayas, C. L., Bolós, M., Zabala, J. C., Rivas, G. and Hernández, F. Tau Structures. Frontiers in Aging Neuroscience 8, 262 (2016). https://doi.org/10.3389/fnagi.2016.00262.
4. Morris, M., Maeda, S., Vossel, K. and Mucke, L. The Many Faces of Tau. Neuron 70(3), 410–426 (2011). https://doi.org/10.1016/j.neuron.2011.04.009.
5. Tapia-Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W. and Quintanilla, R. A. It’s all about tau. Progress in Neurobiology 175, 54–76 (2019). https://doi.org/10.1016/j.pneurobio.2018.12.005.
6. Andreadis, A. Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1739(2), 91–103 (2005). https://doi.org/10.1016/j.bbadis.2004.08.010.
7. Sergeant, N., Delacourte, A. and Buée, L. Tau protein as a differential biomarker of tauopathies. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1739(2), 179–197 (2005). https://doi.org/10.1016/j.bbadis.2004.06.020.
8. Liu, F. and Gong, C.-X. Tau exon 10 alternative splicing and tauopathies. Molecular Neurodegeneration 3, 8 (2008). https://doi.org/10.1186/1750-1326-3-8.
9. García-Escudero, V., Ruiz-Gabarre, D., Gargini, R., Pérez, M., García, E., Cuadros, R., Hernández, I. H., Cabrera, J. R., García-Escudero, R., Lucas, J. J., Hernández, F. and Ávila, J. A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer’s disease. Acta Neuropathologica 142(1), 159–177 (2021). https://doi.org/10.1007/s00401-021-02317-z.
10. Ingram, E. M. and Spillantini, M. G. Tau gene mutations: Dissecting the pathogenesis of FTDP-17. Trends in Molecular Medicine 8(12), 555–562 (2002). https://doi.org/10.1016/S1471-4914(02)02440-1.
11. Johnson, G. V. W. and Stoothoff, W. H. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science 117(24), 5721–5729 (2004). https://doi.org/10.1242/jcs.01558.
12. Tiwari, S., Atluri, V., Kaushik, A., Yndart, A. and Nair, M. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. International Journal of Nanomedicine 14, 5541–5554 (2019). https://doi.org/10.2147/IJN.S200490.
13. Iijima, K., Gatt, A. and Iijima-Ando, K. Tau Ser262 phosphorylation is critical for Aβ42-induced tau toxicity in a transgenic Drosophila model of Alzheimer’s disease. Human Molecular Genetics, 19(15), 2947–2957 (2010). https://doi.org/10.1093/hmg/ddq200.
14. Fulga, T. A., Elson-Schwab, I., Khurana, V., Steinhilb, M. L., Spires, T. L., Hyman, B. T. and Feany, M. B. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nature Cell Biology 9(2), 139–148 (2007). https://doi.org/10.1038/ncb1528.
15. Meraz-Ríos, M. A., Lira-De León, K. I., Campos-Peña, V., De Anda-Hernández, M. A. and Mena-López, R. Tau oligomers and aggregation in Alzheimer’s disease. Journal of Neurochemistry 112(6), 1353–1367 (2010). https://doi.org/10.1111/j.1471-4159.2009.06511.x.
16. Yiannopoulou, K. G. and Papageorgiou, S. G. Current and Future Treatments in Alzheimer Disease: An Update. Journal of Central Nervous System Disease 12, 1179573520907397 (2020). https://doi.org/10.1177/1179573520907397.
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).